Electronic Supplementary Material

Antibody Cocktail Exhibits Broad Neutralization Activity against SARS-CoV-2 and SARS-CoV-2 variants

Yuanyuan Qu¹# • Xueyan Zhang².^{7#} • Meiyu Wang³.^{8#} • Lina Sun¹# • Yongzhong Jiang⁴ • Cheng Li⁵ • Wei Wu¹ • Zhen Chen² • Qiangling Yin¹ • Xiaolin Jiang⁶ • Yang Liu¹ • Chuan Li¹ • Jiandong Li¹ • Tianlei Ying⁵ • Dexin Li¹ • Faxian Zhan⁴ • Youchun Wang³.⁸ • Wuxiang Guan²[™] • Shiwen Wang¹[™] • Mifang Liang¹[™]

- 1. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China;
- 2. Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, China;
- 3. Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China;
- 4. Hubei Provincial Center for Disease Control and Prevention, Wuhan 430065, China;
- 5. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
- 6. Shandong Center for Disease Control and Prevention, Jinan 250014, China.
- 7. University of Chinese Academy of Sciences, Beijing, 100049, China
- 8. Peking Union Medical College, Beijing 100730, China

Supporting information to DOI: 10.1007/s12250-021-00409-4




Fig. S1 Characterization of candidates IgGs. **A** The specificity of candidate antibodies detected by FACS. HEK 293T cells expressing SARS-CoV-2 S protein were incubated with candidate antibodies or isotype IgG (HBV mAb) and then stained with anti-human IgG FITC-conjugated antibody. The X-axis represented the fluorescence intensity of human antibodies labeled by FITC. **B** The affinity between antibodies and S1 was measured by BIAcore 8000 system.